Barclays Increases Icon (NASDAQ:ICLR) Price Target to $150.00

Icon (NASDAQ:ICLR) had its target price upped by equities researchers at Barclays from $120.00 to $150.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the medical research company’s stock. Barclays‘s price target points to a potential upside of 11.55% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Citigroup reduced their price target on Icon from $200.00 to $120.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 11th. Weiss Ratings downgraded Icon from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 18th. JPMorgan Chase & Co. cut their target price on shares of Icon from $175.00 to $120.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. TD Cowen raised shares of Icon from a “hold” rating to a “buy” rating and decreased their target price for the stock from $183.00 to $120.00 in a research note on Wednesday, February 18th. Finally, Robert W. Baird set a $119.00 price target on shares of Icon in a report on Friday, February 13th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, Icon currently has an average rating of “Hold” and an average price target of $153.20.

Icon Trading Down 1.7%

NASDAQ:ICLR traded down $2.34 during trading hours on Friday, reaching $134.47. The company’s stock had a trading volume of 218,518 shares, compared to its average volume of 1,586,565. The firm has a market capitalization of $10.86 billion, a price-to-earnings ratio of 21.79, a PEG ratio of 3.09 and a beta of 1.23. The firm has a 50-day simple moving average of $112.28 and a 200-day simple moving average of $141.50. Icon has a 1 year low of $66.57 and a 1 year high of $211.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06.

Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, May 27th. The medical research company reported $2.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.95 by ($0.43). The business had revenue of $2.11 billion for the quarter, compared to analysts’ expectations of $1.98 billion. Icon had a net margin of 7.40% and a return on equity of 10.58%. The business’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.43 earnings per share. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. Research analysts expect that Icon will post 11.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Icon

Several hedge funds have recently made changes to their positions in ICLR. Muhlenkamp & Co. Inc. bought a new stake in Icon during the third quarter worth about $12,857,000. Mitchell Capital Management Co. bought a new position in shares of Icon during the third quarter valued at approximately $1,627,000. First National Bank of Omaha purchased a new position in shares of Icon during the third quarter valued at approximately $6,267,000. Allspring Global Investments Holdings LLC boosted its position in shares of Icon by 1.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,080,192 shares of the medical research company’s stock worth $203,800,000 after purchasing an additional 11,335 shares in the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Icon in the 3rd quarter worth approximately $39,074,000. 95.61% of the stock is owned by hedge funds and other institutional investors.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.